- Home
- DLY vs TYRA Comparison
DLY vs TYRA Comparison
Compare DLY & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- TYRA
- Stock Information
- Founded
- DLY 2019
- TYRA 2018
- Country
- DLY United States
- TYRA United States
- Employees
- DLY N/A
- TYRA N/A
- Industry
- DLY Investment Managers
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- TYRA Health Care
- Exchange
- DLY Nasdaq
- TYRA Nasdaq
- Market Cap
- DLY 783.0M
- TYRA 1.1B
- IPO Year
- DLY N/A
- TYRA 2021
- Fundamental
- Price
- DLY $16.50
- TYRA $20.59
- Analyst Decision
- DLY
- TYRA Strong Buy
- Analyst Count
- DLY 0
- TYRA 4
- Target Price
- DLY N/A
- TYRA $27.25
- AVG Volume (30 Days)
- DLY 215.9K
- TYRA 136.1K
- Earning Date
- DLY 01-01-0001
- TYRA 08-07-2024
- Dividend Yield
- DLY 8.93%
- TYRA N/A
- EPS Growth
- DLY N/A
- TYRA N/A
- EPS
- DLY N/A
- TYRA N/A
- Revenue
- DLY N/A
- TYRA N/A
- Revenue This Year
- DLY N/A
- TYRA N/A
- Revenue Next Year
- DLY N/A
- TYRA N/A
- P/E Ratio
- DLY N/A
- TYRA N/A
- Revenue Growth
- DLY N/A
- TYRA N/A
- 52 Week Low
- DLY $13.26
- TYRA $10.38
- 52 Week High
- DLY $15.95
- TYRA $24.25
- Technical
- Relative Strength Index (RSI)
- DLY 64.96
- TYRA 45.58
- Support Level
- DLY $16.17
- TYRA $21.16
- Resistance Level
- DLY $16.40
- TYRA $23.63
- Average True Range (ATR)
- DLY 0.13
- TYRA 1.18
- MACD
- DLY 0.01
- TYRA -0.22
- Stochastic Oscillator
- DLY 79.31
- TYRA 10.87
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is organized as a non-diversified, limited-term, closed-end management investment company. The Fund's investment objective is to seek a high level of total return, with an emphasis on current income.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).